Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet need for a product that can safely and specifically disrupt peripheral sensory neurons. N-001 was engineered for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute pain, such as pain following surgery. N-001 is a leading technology in the fight against the opioid crisis, which claims the lives of tens of thousands of Americans each year. A safe, effective treatment for pain, which results in a disease burden of over $635 billion in the US alone, would have a major impact on human health through increased mobility and generally improved life quality. With N-001, we hope to accomplish this without systemic side effects like nausea, dizziness, and addiction.
Headquartered in Lincoln, Nebraska, Neurocarrus was founded by prominent research scientists in the field of protein engineering, and is led by a strong management team with expertise in business, biotechnology and medicine. Since inception, the company has generated extensive in vitro and in vivo data supporting the efficacy of N-001.
Source
